Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.020
-0.040 (-3.77%)
Oct 7, 2025, 2:22 PM EDT - Market open
Biofrontera Revenue
Biofrontera had revenue of $9.03M in the quarter ending June 30, 2025, with 15.19% growth. This brings the company's revenue in the last twelve months to $39.19M, up 11.20% year-over-year. In the year 2024, Biofrontera had annual revenue of $37.32M with 9.54% growth.
Revenue (ttm)
$39.19M
Revenue Growth
+11.20%
P/S Ratio
0.21
Revenue / Employee
$421,376
Employees
93
Market Cap
10.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.32M | 3.25M | 9.54% |
| Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
| Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
| Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
| Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BFRI News
- 11 days ago - Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewsWire
- 14 days ago - Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program - GlobeNewsWire
- 21 days ago - Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk - GlobeNewsWire
- 6 weeks ago - Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 7 weeks ago - Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Appoints George Jones as Chief Commercial Officer - GlobeNewsWire
- 2 months ago - Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 - GlobeNewsWire